CALCRL and cutaneous mastocytosis: To our knowledge, there are no similar studies focusing on the effects of BoNTA on the interictal burden of CM patients, and our results can only be indirectly compared with the results of recent studies that have evaluated changes in interictal burden with anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti-CGRP/anti-CGRPr MAbs) and found that the treatment with galcanezumab resulted in a significant reduction in interictal burden [28,40,41].